Approval · Notice of Compliance 31793 · 2023
AIMOVIG: Notice of Compliance 31793
Issued October 6, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31793
- Date
- October 6, 2023
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Change in drug product manufacturing process
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AIMOVIG | Not yet assigned | — |